Availability, affordability and stock-outs of commodities for the treatment of snakebite in Kenya.

<h4>Background</h4>Annually, about 2.7 million snakebite envenomings occur globally. Alongside antivenom, patients usually require additional care to treat envenoming symptoms and antivenom side effects. Efforts are underway to improve snakebite care, but evidence from the ground to info...

Full description

Bibliographic Details
Main Authors: Gaby Isabelle Ooms, Janneke van Oirschot, Dorothy Okemo, Benjamin Waldmann, Eugene Erulu, Aukje K Mantel-Teeuwisse, Hendrika A van den Ham, Tim Reed
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2021-08-01
Series:PLoS Neglected Tropical Diseases
Online Access:https://doi.org/10.1371/journal.pntd.0009702
_version_ 1818937449278078976
author Gaby Isabelle Ooms
Janneke van Oirschot
Dorothy Okemo
Benjamin Waldmann
Eugene Erulu
Aukje K Mantel-Teeuwisse
Hendrika A van den Ham
Tim Reed
author_facet Gaby Isabelle Ooms
Janneke van Oirschot
Dorothy Okemo
Benjamin Waldmann
Eugene Erulu
Aukje K Mantel-Teeuwisse
Hendrika A van den Ham
Tim Reed
author_sort Gaby Isabelle Ooms
collection DOAJ
description <h4>Background</h4>Annually, about 2.7 million snakebite envenomings occur globally. Alongside antivenom, patients usually require additional care to treat envenoming symptoms and antivenom side effects. Efforts are underway to improve snakebite care, but evidence from the ground to inform this is scarce. This study, therefore, investigated the availability, affordability, and stock-outs of antivenom and commodities for supportive snakebite care in health facilities across Kenya.<h4>Methodology/principal findings</h4>This study used an adaptation of the standardised World Health Organization (WHO)/Health Action International methodology. Data on commodity availability, prices and stock-outs were collected in July-August 2020 from public (n = 85), private (n = 36), and private not-for-profit (n = 12) facilities in Kenya. Stock-outs were measured retrospectively for a twelve-month period, enabling a comparison of a pre-COVID-19 period to stock-outs during COVID-19. Affordability was calculated using the wage of a lowest-paid government worker (LPGW) and the impoverishment approach. Accessibility was assessed combining the WHO availability target (≥80%) and LPGW affordability (<1 day's wage) measures. Overall availability of snakebite commodities was low (43.0%). Antivenom was available at 44.7% of public- and 19.4% of private facilities. Stock-outs of any snakebite commodity were common in the public- (18.6%) and private (11.7%) sectors, and had worsened during COVID-19 (10.6% versus 17.0% public sector, 8.4% versus 11.7% private sector). Affordability was not an issue in the public sector, while in the private sector the median cost of one vial of antivenom was 14.4 days' wage for an LPGW. Five commodities in the public sector and two in the private sector were deemed accessible.<h4>Conclusions</h4>Access to snakebite care is problematic in Kenya and seemed to have worsened during COVID-19. To improve access, efforts should focus on ensuring availability at both lower- and higher-level facilities, and improving the supply chain to reduce stock-outs. Including antivenom into Universal Health Coverage benefits packages would further facilitate accessibility.
first_indexed 2024-12-20T05:52:08Z
format Article
id doaj.art-7013aec8c4c245229713a461ad10abd0
institution Directory Open Access Journal
issn 1935-2727
1935-2735
language English
last_indexed 2024-12-20T05:52:08Z
publishDate 2021-08-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS Neglected Tropical Diseases
spelling doaj.art-7013aec8c4c245229713a461ad10abd02022-12-21T19:51:09ZengPublic Library of Science (PLoS)PLoS Neglected Tropical Diseases1935-27271935-27352021-08-01158e000970210.1371/journal.pntd.0009702Availability, affordability and stock-outs of commodities for the treatment of snakebite in Kenya.Gaby Isabelle OomsJanneke van OirschotDorothy OkemoBenjamin WaldmannEugene EruluAukje K Mantel-TeeuwisseHendrika A van den HamTim Reed<h4>Background</h4>Annually, about 2.7 million snakebite envenomings occur globally. Alongside antivenom, patients usually require additional care to treat envenoming symptoms and antivenom side effects. Efforts are underway to improve snakebite care, but evidence from the ground to inform this is scarce. This study, therefore, investigated the availability, affordability, and stock-outs of antivenom and commodities for supportive snakebite care in health facilities across Kenya.<h4>Methodology/principal findings</h4>This study used an adaptation of the standardised World Health Organization (WHO)/Health Action International methodology. Data on commodity availability, prices and stock-outs were collected in July-August 2020 from public (n = 85), private (n = 36), and private not-for-profit (n = 12) facilities in Kenya. Stock-outs were measured retrospectively for a twelve-month period, enabling a comparison of a pre-COVID-19 period to stock-outs during COVID-19. Affordability was calculated using the wage of a lowest-paid government worker (LPGW) and the impoverishment approach. Accessibility was assessed combining the WHO availability target (≥80%) and LPGW affordability (<1 day's wage) measures. Overall availability of snakebite commodities was low (43.0%). Antivenom was available at 44.7% of public- and 19.4% of private facilities. Stock-outs of any snakebite commodity were common in the public- (18.6%) and private (11.7%) sectors, and had worsened during COVID-19 (10.6% versus 17.0% public sector, 8.4% versus 11.7% private sector). Affordability was not an issue in the public sector, while in the private sector the median cost of one vial of antivenom was 14.4 days' wage for an LPGW. Five commodities in the public sector and two in the private sector were deemed accessible.<h4>Conclusions</h4>Access to snakebite care is problematic in Kenya and seemed to have worsened during COVID-19. To improve access, efforts should focus on ensuring availability at both lower- and higher-level facilities, and improving the supply chain to reduce stock-outs. Including antivenom into Universal Health Coverage benefits packages would further facilitate accessibility.https://doi.org/10.1371/journal.pntd.0009702
spellingShingle Gaby Isabelle Ooms
Janneke van Oirschot
Dorothy Okemo
Benjamin Waldmann
Eugene Erulu
Aukje K Mantel-Teeuwisse
Hendrika A van den Ham
Tim Reed
Availability, affordability and stock-outs of commodities for the treatment of snakebite in Kenya.
PLoS Neglected Tropical Diseases
title Availability, affordability and stock-outs of commodities for the treatment of snakebite in Kenya.
title_full Availability, affordability and stock-outs of commodities for the treatment of snakebite in Kenya.
title_fullStr Availability, affordability and stock-outs of commodities for the treatment of snakebite in Kenya.
title_full_unstemmed Availability, affordability and stock-outs of commodities for the treatment of snakebite in Kenya.
title_short Availability, affordability and stock-outs of commodities for the treatment of snakebite in Kenya.
title_sort availability affordability and stock outs of commodities for the treatment of snakebite in kenya
url https://doi.org/10.1371/journal.pntd.0009702
work_keys_str_mv AT gabyisabelleooms availabilityaffordabilityandstockoutsofcommoditiesforthetreatmentofsnakebiteinkenya
AT jannekevanoirschot availabilityaffordabilityandstockoutsofcommoditiesforthetreatmentofsnakebiteinkenya
AT dorothyokemo availabilityaffordabilityandstockoutsofcommoditiesforthetreatmentofsnakebiteinkenya
AT benjaminwaldmann availabilityaffordabilityandstockoutsofcommoditiesforthetreatmentofsnakebiteinkenya
AT eugeneerulu availabilityaffordabilityandstockoutsofcommoditiesforthetreatmentofsnakebiteinkenya
AT aukjekmantelteeuwisse availabilityaffordabilityandstockoutsofcommoditiesforthetreatmentofsnakebiteinkenya
AT hendrikaavandenham availabilityaffordabilityandstockoutsofcommoditiesforthetreatmentofsnakebiteinkenya
AT timreed availabilityaffordabilityandstockoutsofcommoditiesforthetreatmentofsnakebiteinkenya